This is a summary of the European public assessment report (EPAR) for Ebixa. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ebixa.
Therapeutic Indication
Treatment of patients with moderate to severe Alzheimer's disease.
Therapeutic Area (MeSH)
ATC Code
N06DX01
ATC Item
N/A
Pharmacotherapeutic Group
Other anti-dementia drugs
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| memantine hydrochloride | N/A | memantine hydrochloride |
EMA Name
Ebixa
Medicine Name
Ebixa
Aliases
N/ANo risk management plan link.
